Combretastatin A1 Phosphate

N/A

Report date: 2024/11/06 20:00:41
NME

Base Information

Drug NameCombretastatin A1 Phosphate
Drug Alias NameCombretastatin A1 di-phosphateCombrestatin A1 diphosphateCA1PCA1OXi-4503
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsVascular disrupting agents (VDA)
TargetsTubulin
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOncotelic Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesOncotelic Therapeutics IncUniversity Of Florida
Active IndicationsN/A
Inactive IndicationsSolid tumoursMyelodysplastic SyndromesNeoplasm Metastasis +[4] 

Other Information

ATC CodeN/A
Related LinksN/A